Ellis David, Patel Yogen, Yau Shu C, Hodgson Shirley V, Abbs Stephen J
Genetics Centre, Guy's & St Thomas' Hospital NHS Trust, London, SE1 9RT, UK.
Fam Cancer. 2006;5(4):323-6. doi: 10.1007/s10689-006-0001-0. Epub 2006 May 25.
BRCA1 exon deletions and duplications have been reported in a number of studies, and in order to design an effective mutation screening strategy in a diagnostic setting it is import to determine the frequency of this type of mutation in breast and ovarian cancer patients. We have designed and applied quantitative fluorescent PCR (QF-PCR) assays to screen for BRCA1 exon rearrangements in breast cancer patients both with and without a family history. A panel of 182 familial patients was screened, and an exon 3-7 deletion mutation was detected in a patient with a family history of breast and ovarian cancer. Additionally, we detected a duplication of exons 18-19 in an early onset sporadic breast cancer patient from a panel of 100 patients tested. These data indicate that in the absence of any founder mutations, screening for BRCA1 exon rearrangements does not significantly increase the overall BRCA1 mutation detection rate in patients referred to a genetics clinic because of either a family history and/or an early onset of disease.
多项研究报告了BRCA1外显子缺失和重复情况,为在诊断环境中设计有效的突变筛查策略,确定此类突变在乳腺癌和卵巢癌患者中的频率很重要。我们设计并应用了定量荧光PCR(QF-PCR)检测方法,对有和没有家族史的乳腺癌患者进行BRCA1外显子重排筛查。对一组182名家族性患者进行了筛查,在一名有乳腺癌和卵巢癌家族史的患者中检测到外显子3 - 7缺失突变。此外,在测试的一组100名患者中,我们在一名早发性散发性乳腺癌患者中检测到外显子18 - 19重复。这些数据表明,在没有任何奠基者突变的情况下,对BRCA1外显子重排进行筛查并不会显著提高因家族史和/或疾病早发而转诊至遗传学诊所的患者的总体BRCA1突变检测率。